DFN15 Versus Placebo in Patients With Migraine Headaches
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with a history of episodic migraine (as defined by International Classification of Headache Disorders [ICHD]-228) who experience an average of 2 to 6 migraine attacks a month for the past 12 months with no more than 14 headache days per month, and with at least 48 hours of headache-free time between migraine attacks;
Patients with onset of migraine with or without aura before age 50;
Patients who have migraine with or without aura, in which the aura cannot last longer than 60 minutes;
Patients who report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity scale.
Patients with medication overuse headache (MOH) as defined by ICHD-228:
Opioids ≥ 10 days a month during the 90 days prior to screening
Combination medications (eg, Fiorinal® ≥ 10 days a month)
Nonsteroidal anti-inflammatory drugs (NSAIDs) or other simple medications > 14 days a month during the 90 days prior to screening
Triptans or ergots ≥ 10 days a month during the 90 days prior to screening
Patients on unstable dosages of chronic medications during the 3 months prior to and through screening, or who are not willing or able to maintain a stable pre-study dose throughout study participation;
Patients with more than 6 migraine attacks a month and/or more than 14 headache days a month (based upon patient self-report);
Patients with hemiplegic migraine or migraine with brain stem aura or other forms of neurologically complicated migraine;
Patients with atypical aura;
Patients with prolonged aura (more than 1 hour).
Patients with a history of stroke or transient ischemic attack;
Patients with a history of migralepsy or a concurrent diagnosis of seizure disorder;
Patients who cannot differentiate between a migraine headache and a tension-type or cluster headache or any other non-migraine headache;
Patients with a history of more than 10 tension-type headaches per month;
Patients with a history of cluster headache;
Patients with a diagnosis of ICHD-2 "probable migraine";
Patients with severe renal impairment (defined as serum creatinine > 1.9 mg/dL);
Patients with serum total bilirubin > 1.9 mg/dL;
Patients with serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 3 times the upper limit of normal;
Patients with positive serology for human immunodeficiency virus (HIV), Hepatitis B surface antigen, Hepatitis C antibody.
Patients with a history of alcohol or substance abuse (including marijuana and medical marijuana) within 1 year that would compromise data collection;
Patients with a history of or current neurological or psychiatric impairment, or cognitive dysfunction that, in the opinion of the investigator, would compromise data collection;
Patients with any other medical condition that, in the judgment of the investigator or medical monitor, would confound the objectives of the study (eg, cancer history [except basal cell carcinoma], systemic lupus erythematosus);
Patients who have participated in a clinical trial involving any medication during the past 30 days or 5 half-lives of the study medication, whichever is longer